A long-term dose-response study of mitomycin in glaucoma filtration surgery

Alan L. Robin, R. Ramahrishnan, R. Krishnadas, Scott D. Smith, Joanne Katz, S. Selvaraj, Gregory L. Shuta, Rohit Bhatnagar

Research output: Contribution to journalArticle

Abstract

Objective: To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications. Methods: We performed a prospective double-masked, placebo-controlled, 1-year study evaluating the decrease in IOP and fewer complications of fornix-based trabeculectomy surgery in 300 eyes equally divided among therapy with placebo; mitomycin, 0.2 mg/mL, applied for 2 minutes; mitomycin, 0.2 mg/mL, applied for 4 minutes; or mitomycin, 0.4 mg/mL, applied for 2 minutes. All of the eyes had vertical and horizontal cupdisc ratios greater than 0.7. Results: We observed significant treatment-related differences in IOP, with a decrease in IOP in all 3 mitomycin-treated groups for all of the times beyond 1 month. The number of eyes achieving strict IOP control and the development of cataract suggest a possible dose-response effect for concentration and time of exposure. Progressive lens opacification was the most frequent complication in 54 eyes (18.1%). The incidence of progressive lens changes markedly increased in subjects receiving 4 minutes of mitomycin therapy. Cataract formation was unrelated to IOP. Other complications were rare. Macular folds developed in 6 patients, with visual acuity returning to better than 20/40 in all but 1 patient. Conclusions: A possible dose-response relationship seemed to exist between the concentration of and duration of exposure to mitomycin. Length of exposure seems to be more important than concentration. The benefits of additional decreases in IOP must be weighed against the potential for increases in the risk of complications.

Original languageEnglish (US)
Pages (from-to)969-974
Number of pages6
JournalArchives of Ophthalmology
Volume115
Issue number8
StatePublished - 1997

Fingerprint

Filtering Surgery
Mitomycin
Intraocular Pressure
Glaucoma
Cataract
Lenses
Placebos
Trabeculectomy
Visual Acuity
Therapeutics
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Robin, A. L., Ramahrishnan, R., Krishnadas, R., Smith, S. D., Katz, J., Selvaraj, S., ... Bhatnagar, R. (1997). A long-term dose-response study of mitomycin in glaucoma filtration surgery. Archives of Ophthalmology, 115(8), 969-974.

A long-term dose-response study of mitomycin in glaucoma filtration surgery. / Robin, Alan L.; Ramahrishnan, R.; Krishnadas, R.; Smith, Scott D.; Katz, Joanne; Selvaraj, S.; Shuta, Gregory L.; Bhatnagar, Rohit.

In: Archives of Ophthalmology, Vol. 115, No. 8, 1997, p. 969-974.

Research output: Contribution to journalArticle

Robin, AL, Ramahrishnan, R, Krishnadas, R, Smith, SD, Katz, J, Selvaraj, S, Shuta, GL & Bhatnagar, R 1997, 'A long-term dose-response study of mitomycin in glaucoma filtration surgery', Archives of Ophthalmology, vol. 115, no. 8, pp. 969-974.
Robin AL, Ramahrishnan R, Krishnadas R, Smith SD, Katz J, Selvaraj S et al. A long-term dose-response study of mitomycin in glaucoma filtration surgery. Archives of Ophthalmology. 1997;115(8):969-974.
Robin, Alan L. ; Ramahrishnan, R. ; Krishnadas, R. ; Smith, Scott D. ; Katz, Joanne ; Selvaraj, S. ; Shuta, Gregory L. ; Bhatnagar, Rohit. / A long-term dose-response study of mitomycin in glaucoma filtration surgery. In: Archives of Ophthalmology. 1997 ; Vol. 115, No. 8. pp. 969-974.
@article{55d54bc9aada465c84b4d36770b9f49b,
title = "A long-term dose-response study of mitomycin in glaucoma filtration surgery",
abstract = "Objective: To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications. Methods: We performed a prospective double-masked, placebo-controlled, 1-year study evaluating the decrease in IOP and fewer complications of fornix-based trabeculectomy surgery in 300 eyes equally divided among therapy with placebo; mitomycin, 0.2 mg/mL, applied for 2 minutes; mitomycin, 0.2 mg/mL, applied for 4 minutes; or mitomycin, 0.4 mg/mL, applied for 2 minutes. All of the eyes had vertical and horizontal cupdisc ratios greater than 0.7. Results: We observed significant treatment-related differences in IOP, with a decrease in IOP in all 3 mitomycin-treated groups for all of the times beyond 1 month. The number of eyes achieving strict IOP control and the development of cataract suggest a possible dose-response effect for concentration and time of exposure. Progressive lens opacification was the most frequent complication in 54 eyes (18.1{\%}). The incidence of progressive lens changes markedly increased in subjects receiving 4 minutes of mitomycin therapy. Cataract formation was unrelated to IOP. Other complications were rare. Macular folds developed in 6 patients, with visual acuity returning to better than 20/40 in all but 1 patient. Conclusions: A possible dose-response relationship seemed to exist between the concentration of and duration of exposure to mitomycin. Length of exposure seems to be more important than concentration. The benefits of additional decreases in IOP must be weighed against the potential for increases in the risk of complications.",
author = "Robin, {Alan L.} and R. Ramahrishnan and R. Krishnadas and Smith, {Scott D.} and Joanne Katz and S. Selvaraj and Shuta, {Gregory L.} and Rohit Bhatnagar",
year = "1997",
language = "English (US)",
volume = "115",
pages = "969--974",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - A long-term dose-response study of mitomycin in glaucoma filtration surgery

AU - Robin, Alan L.

AU - Ramahrishnan, R.

AU - Krishnadas, R.

AU - Smith, Scott D.

AU - Katz, Joanne

AU - Selvaraj, S.

AU - Shuta, Gregory L.

AU - Bhatnagar, Rohit

PY - 1997

Y1 - 1997

N2 - Objective: To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications. Methods: We performed a prospective double-masked, placebo-controlled, 1-year study evaluating the decrease in IOP and fewer complications of fornix-based trabeculectomy surgery in 300 eyes equally divided among therapy with placebo; mitomycin, 0.2 mg/mL, applied for 2 minutes; mitomycin, 0.2 mg/mL, applied for 4 minutes; or mitomycin, 0.4 mg/mL, applied for 2 minutes. All of the eyes had vertical and horizontal cupdisc ratios greater than 0.7. Results: We observed significant treatment-related differences in IOP, with a decrease in IOP in all 3 mitomycin-treated groups for all of the times beyond 1 month. The number of eyes achieving strict IOP control and the development of cataract suggest a possible dose-response effect for concentration and time of exposure. Progressive lens opacification was the most frequent complication in 54 eyes (18.1%). The incidence of progressive lens changes markedly increased in subjects receiving 4 minutes of mitomycin therapy. Cataract formation was unrelated to IOP. Other complications were rare. Macular folds developed in 6 patients, with visual acuity returning to better than 20/40 in all but 1 patient. Conclusions: A possible dose-response relationship seemed to exist between the concentration of and duration of exposure to mitomycin. Length of exposure seems to be more important than concentration. The benefits of additional decreases in IOP must be weighed against the potential for increases in the risk of complications.

AB - Objective: To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications. Methods: We performed a prospective double-masked, placebo-controlled, 1-year study evaluating the decrease in IOP and fewer complications of fornix-based trabeculectomy surgery in 300 eyes equally divided among therapy with placebo; mitomycin, 0.2 mg/mL, applied for 2 minutes; mitomycin, 0.2 mg/mL, applied for 4 minutes; or mitomycin, 0.4 mg/mL, applied for 2 minutes. All of the eyes had vertical and horizontal cupdisc ratios greater than 0.7. Results: We observed significant treatment-related differences in IOP, with a decrease in IOP in all 3 mitomycin-treated groups for all of the times beyond 1 month. The number of eyes achieving strict IOP control and the development of cataract suggest a possible dose-response effect for concentration and time of exposure. Progressive lens opacification was the most frequent complication in 54 eyes (18.1%). The incidence of progressive lens changes markedly increased in subjects receiving 4 minutes of mitomycin therapy. Cataract formation was unrelated to IOP. Other complications were rare. Macular folds developed in 6 patients, with visual acuity returning to better than 20/40 in all but 1 patient. Conclusions: A possible dose-response relationship seemed to exist between the concentration of and duration of exposure to mitomycin. Length of exposure seems to be more important than concentration. The benefits of additional decreases in IOP must be weighed against the potential for increases in the risk of complications.

UR - http://www.scopus.com/inward/record.url?scp=0030842393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030842393&partnerID=8YFLogxK

M3 - Article

VL - 115

SP - 969

EP - 974

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 8

ER -